What is Ekso Bionics's earnings per share (EPS)?

Ekso Bionics (EKSO) reported diluted earnings per share of -$4.91 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Ekso Bionics Financials

EKSO

Trailing 12 months to March 31, 2026

Revenue $11.6M -34.1% YoY

Net Income -$15.7M -45.4% YoY

EPS (Diluted) -$4.91 FY2025 annual

Free Cash Flow -$12.1M -44.8% YoY

Source SEC Filings (10-K/10-Q) Latest period Q1 FY2026, ended Mar 31, 2026 Reported Apr 28, 2026 Currency USD FYE December

Ekso Bionics (EKSO) reported $11.6M in revenue over the twelve months to Mar 31, 2026, down 34.1% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 14 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI EKSO FY2025 2026-08-29

Recurring operating cash consumption is the dominant mechanic, with external financing repeatedly filling the gap left by the business.

Revenue fell to $12.8M in FY2025 while gross margin held at 53.5%, making lower volume and weak fixed-cost absorption more plausible explanations than a collapse in product-level economics. Operating cash flow was -$11.8M versus free cash flow of -$12.0M, showing that nearly all cash pressure came from operations rather than heavy capital spending.

Gross margin improved from 48.1% in FY2022 to 53.5% in FY2025, a favorable unit-economics shift that still did not cover the operating base. In FY2025, SG&A and R&D totaled $13.0M against $6.8M of gross profit, explaining why scale—not gross margin alone—remains the constraint.

The current ratio fell from 2.5x in FY2024 to 1.6x in FY2025, showing less short-term balance-sheet flexibility as losses continued. FY2025 financing provided $6.6M against operating cash flow of -$11.8M; the reported liquidity comparison was only 1.2 months, underscoring the balance sheet’s reliance on external capital.

Financial Health Signals

Financial Health Score 36/100

Scored as: Emerging companies peer group

Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Ekso Bionics's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Cash Runway

Dilution

R&D Intensity

Revenue Progress

Burn Trend

Balance Sheet

Altman Z-Score Distress

-17.22

Ekso Bionics scores -17.22, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($42.0M) relative to total liabilities ($11.1M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

1/8

Ekso Bionics passes 1 of 8 computable financial strength tests (1 of the nine could not be computed from available data). No profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), 1 of 2 efficiency signals pass.

Earnings Quality No Cash Backing

N/A

Ekso Bionics reported a net loss of $11.7M while operations used $11.8M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk

N/A

Ekso Bionics reported an operating loss of $13.3M against $309K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$12.8M

YoY-28.6%

5Y CAGR+7.6%

10Y CAGR+4.0%

Ekso Bionics generated $12.8M in revenue in fiscal year 2025. This represents a decrease of 28.6% from the prior year.

EBITDA

-$11.8M

YoY-32.8%

Ekso Bionics's EBITDA was -$11.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 32.8% from the prior year.

Net Income

-$11.7M

YoY-3.2%

Ekso Bionics reported -$11.7M in net income in fiscal year 2025. This represents a decrease of 3.2% from the prior year.

EPS (Diluted)

-$4.91

Ekso Bionics earned -$4.91 per diluted share (EPS) in fiscal year 2025.

Cash & Balance Sheet

Free Cash Flow

-$12.0M

YoY-21.3%

Ekso Bionics recorded an outflow of $12.0M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents a decrease of 21.3% from the prior year.

Cash & Debt

$1.2M

YoY-74.0%

5Y CAGR-38.1%

10Y CAGR-24.5%

Ekso Bionics held $1.2M in cash as of fiscal year 2025; long-term debt is not reported for that period.

Shares Outstanding

Ekso Bionics had 4M shares outstanding in fiscal year 2025.

Dividends Per Share

Not reported for fiscal year 2025.

Margins & Returns

Gross Margin

53.5%

YoY+0.4pp

5Y CAGR-3.6pp

10Y CAGR+39.9pp

Ekso Bionics's gross margin was 53.5% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 0.4 percentage points from the prior year.

Net Margin

-91.4%

YoY-28.2pp

Ekso Bionics's net profit margin was -91.4% in fiscal year 2025, showing the share of revenue converted to profit. This is down 28.2 percentage points from the prior year.

Return on Equity

-129.6%

YoY-40.4pp

5Y CAGR+227.3pp

10Y CAGR+92.8pp

Ekso Bionics's ROE was -129.6% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 40.4 percentage points from the prior year.

Operating Margin

Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Capital Allocation

R&D Spending

$3.0M

YoY-21.8%

5Y CAGR+4.1%

10Y CAGR-7.3%

Ekso Bionics invested $3.0M in research and development in fiscal year 2025. This represents a decrease of 21.8% from the prior year.

Capital Expenditures

$188K

YoY+408.1%

10Y CAGR-18.7%

Ekso Bionics invested $188K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 408.1% from the prior year.

Share Buybacks

Not reported for fiscal year 2025.

EKSO Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

EKSO quarterly income statement

Metric	TTM	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12
Revenue	$11.6M	$12.8M-28.6%	$17.9M-1.9%	$18.3M+41.6%	$12.9M+14.8%	$11.2M+26.6%	$8.9M-36.2%	$13.9M+22.8%	$11.3M+54.1%	$7.4M-48.3%	$14.2M+64.2%	$8.7M+62.6%	$5.3M+61.3%	$3.3M	N/A
Cost of Revenue	$5.5M	$6.0M-29.2%	$8.4M-8.5%	$9.2M+37.4%	$6.7M+48.9%	$4.5M+18.0%	$3.8M-46.7%	$7.2M+1.9%	$7.0M+32.9%	$5.3M-53.1%	$11.3M+50.7%	$7.5M+98.6%	$3.8M+38.8%	$2.7M	N/A
Gross Profit	$6.1M	$6.8M-28.0%	$9.5M+4.8%	$9.1M+46.1%	$6.2M-7.9%	$6.7M+33.1%	$5.1M-25.0%	$6.8M+57.0%	$4.3M+108.3%	$2.1M-29.8%	$2.9M+150.0%	$1.2M-24.4%	$1.6M+165.6%	$587K	N/A
R&D Expenses	$2.6M	$3.0M-21.8%	$3.9M-22.9%	$5.0M+38.6%	$3.6M+42.3%	$2.5M+3.0%	$2.5M-46.2%	$4.6M-21.4%	$5.8M-38.3%	$9.5M+6.8%	$8.9M+37.0%	$6.5M+67.5%	$3.9M+44.5%	$2.7M	N/A
SG&A Expenses	$11.5M	$10.0M+13.6%	$8.8M-17.8%	$10.7M-2.7%	$11.0M+2.5%	$10.7M+39.2%	$7.7M+4.0%	$7.4M-36.5%	$11.7M+8.9%	$10.7M-1.3%	$10.9M+55.0%	$7.0M-5.4%	$7.4M+89.1%	$3.9M+289537.3%	$1K
Operating Income	-$15.5M	-$13.3M-27.4%	-$10.5M+30.8%	-$15.1M+2.9%	-$15.6M-12.5%	-$13.8M-4.0%	-$13.3M+20.1%	-$16.6M+38.4%	-$27.0M+14.5%	-$31.6M-14.6%	-$27.6M-27.9%	-$21.6M-28.4%	-$16.8M-63.1%	-$10.3M	N/A
Interest Expense	$380K	$309K+14.9%	$269K-10.9%	$302K+93.6%	$156K+38.1%	$113K-18.7%	$139K-63.8%	$384K-36.0%	$600K-7.4%	$648K+3950.0%	$16K+23.1%	$13K-97.0%	$435K-74.8%	$1.7M	N/A
Income Tax	N/A	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$15.7M	-$11.7M-3.2%	-$11.3M+25.5%	-$15.2M-0.8%	-$15.1M-54.4%	-$9.8M+38.3%	-$15.8M-30.4%	-$12.1M+55.1%	-$27.0M+7.3%	-$29.1M-24.1%	-$23.5M-19.8%	-$19.6M+42.0%	-$33.8M-184.1%	-$11.9M	N/A
EPS (Diluted)	—	-$4.91	-$8.43	-$1.10+5.2%	-$1.16-31.8%	-$0.88	-$2.21+12.6%	-$2.53	-$0.44	-$0.82	-$2.05-12.0%	-$1.83	-$3.02	-$0.57	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Revenue	$2.1M-31.8%	$3.1M-25.7%	$4.2M+105.5%	$2.1M-39.1%	$3.4M-33.7%	$5.1M+23.3%	$4.1M-16.6%	$5.0M
Cost of Revenue	$1.1M-27.4%	$1.5M-12.5%	$1.7M+35.5%	$1.2M-21.1%	$1.6M-34.0%	$2.4M+23.8%	$1.9M-17.0%	$2.3M
Gross Profit	$1.1M-35.7%	$1.7M-34.4%	$2.5M+211.2%	$819K-54.7%	$1.8M-33.5%	$2.7M+22.9%	$2.2M-16.2%	$2.6M
R&D Expenses	$583K-9.0%	$641K+16.5%	$550K-35.4%	$852K-13.8%	$988K+16.9%	$845K+8.8%	$777K-30.4%	$1.1M
SG&A Expenses	$4.1M+31.1%	$3.1M+48.2%	$2.1M-7.3%	$2.3M-11.7%	$2.6M+15.2%	$2.2M-4.2%	$2.3M+15.0%	$2.0M
Operating Income	-$5.6M-24.6%	-$4.5M-221.6%	-$1.4M+64.7%	-$4.0M-15.6%	-$3.4M-54.3%	-$2.2M+15.5%	-$2.6M-13.0%	-$2.3M
Interest Expense	$143K-7.1%	$154K+755.6%	$18K-72.3%	$65K-9.7%	$72K+22.0%	$59K-25.3%	$79K+6.8%	$74K
Net Income	-$6.9M-47.3%	-$4.7M-228.9%	-$1.4M+47.5%	-$2.7M+6.3%	-$2.9M+15.3%	-$3.4M-64.7%	-$2.1M+14.2%	-$2.4M
EPS (Diluted)	-$2.04	N/A	-$0.54+56.5%	-$1.24	-$1.84	N/A	-$1.53+23.1%	-$1.99

Not reported in any period shown, so not listed: Income Tax.

EKSO Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

EKSO quarterly balance sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12
Total Assets	$20.1M-24.5%	$26.7M-7.8%	$28.9M-29.3%	$40.9M-16.8%	$49.2M+138.7%	$20.6M-6.0%	$21.9M+24.1%	$17.7M-53.5%	$38.0M+55.5%	$24.4M-24.1%	$32.2M-3.8%	$33.5M+408.4%	$6.6M+21883.3%	$30K
Current Assets	$14.0M-25.4%	$18.8M-6.8%	$20.2M-34.9%	$31.0M-35.1%	$47.8M+159.5%	$18.4M-2.1%	$18.8M+25.7%	$15.0M-57.2%	$34.9M+68.9%	$20.7M-17.9%	$25.2M-14.0%	$29.3M+814.8%	$3.2M	N/A
Cash & Equivalents	$1.2M-74.0%	$4.5M-48.0%	$8.6M-57.9%	$20.5M-49.2%	$40.4M+214.2%	$12.9M+18.3%	$10.9M+42.0%	$7.7M-72.5%	$27.8M+65.1%	$16.8M-13.8%	$19.6M-22.4%	$25.2M+3029.2%	$805K	N/A
Inventory	$4.8M+5.5%	$4.6M-9.5%	$5.0M-2.6%	$5.2M+131.4%	$2.2M+13.3%	$2.0M-20.5%	$2.5M-26.2%	$3.4M+11.4%	$3.0M+94.4%	$1.6M+47.3%	$1.1M+69.8%	$622K-14.2%	$725K	N/A
Accounts Receivable	$7.3M+1.0%	$7.2M+28.2%	$5.6M+22.1%	$4.6M-0.8%	$4.7M+44.6%	$3.2M-38.1%	$5.2M+42.3%	$3.7M+32.6%	$2.8M+55.1%	$1.8M-14.0%	$2.1M+33.6%	$1.5M+182.1%	$549K	N/A
Goodwill	$431K0.0%	$431K0.0%	$431K0.0%	$431K	$0	$0-100.0%	$189K0.0%	$189K0.0%	$189K0.0%	$189K0.0%	$189K	$0	N/A	N/A
Total Liabilities	$11.1M-20.5%	$13.9M-14.5%	$16.3M+5.5%	$15.5M+29.4%	$11.9M-26.1%	$16.2M+6.9%	$15.1M+1.3%	$14.9M-10.1%	$16.6M-7.2%	$17.9M-23.5%	$23.4M+119.1%	$10.7M-75.2%	$43.0M+71.0%	$25.1M
Current Liabilities	$8.6M+14.6%	$7.5M-7.1%	$8.1M-11.8%	$9.2M+34.2%	$6.9M+37.8%	$5.0M-36.5%	$7.8M-22.3%	$10.1M+10.0%	$9.2M+44.8%	$6.3M-26.6%	$8.6M+30.3%	$6.6M-45.1%	$12.1M	N/A
Long-Term Debt	N/A	N/A	N/A	N/A	$2.0M+0.2%	$2.0M+388.7%	$407K-84.6%	$2.6M-45.2%	$4.8M+2996.2%	$156K-36.6%	$246K+90.7%	$129K	N/A	N/A
Total Equity	$9.0M-29.0%	$12.7M+0.8%	$12.6M-50.5%	$25.4M-31.6%	$37.2M+739.4%	$4.4M-34.8%	$6.8M+149.2%	$2.7M-87.2%	$21.4M+227.5%	$6.5M-25.9%	$8.8M-61.4%	$22.8M+162.7%	-$36.4M-45.0%	-$25.1M
Retained Earnings	-$262.4M-4.8%	-$250.5M-4.7%	-$239.1M-6.8%	-$223.9M-7.2%	-$208.9M-4.9%	-$199.1M-8.6%	-$183.3M-7.1%	-$171.1M-18.7%	-$144.2M-25.5%	-$114.9M-25.7%	-$91.4M-27.3%	-$71.8M-88.8%	-$38.0M	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Total Assets	$19.7M-2.2%	$20.1M-7.2%	$21.7M-6.5%	$23.2M-15.2%	$27.3M+2.5%	$26.7M-8.8%	$29.2M+8.2%	$27.0M
Current Assets	$14.1M0.0%	$14.0M-5.0%	$14.8M-7.4%	$16.0M-20.4%	$20.1M+6.5%	$18.8M-10.6%	$21.1M+13.0%	$18.6M
Cash & Equivalents	$4.0M+241.6%	$1.2M-57.1%	$2.7M-48.1%	$5.2M-34.9%	$8.1M+79.3%	$4.5M-45.8%	$8.3M+40.9%	$5.9M
Inventory	$4.6M-3.6%	$4.8M-4.0%	$5.0M-7.6%	$5.4M+9.6%	$5.0M+8.6%	$4.6M-9.1%	$5.0M+1.1%	$5.0M
Accounts Receivable	$4.5M-37.9%	$7.3M+20.8%	$6.0M+33.4%	$4.5M-29.8%	$6.5M-10.8%	$7.2M+3.9%	$7.0M+6.8%	$6.5M
Goodwill	$431K0.0%	$431K0.0%	$431K0.0%	$431K0.0%	$431K0.0%	$431K0.0%	$431K0.0%	$431K
Total Liabilities	$13.9M+25.7%	$11.1M-7.5%	$12.0M-2.1%	$12.2M-16.3%	$14.6M+4.8%	$13.9M-2.7%	$14.3M-3.9%	$14.9M
Current Liabilities	$9.1M+5.3%	$8.6M-3.4%	$8.9M+33.1%	$6.7M-21.5%	$8.6M+13.5%	$7.5M+0.4%	$7.5M-2.6%	$7.7M
Long-Term Debt	$520K	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$2.1M-76.8%	$9.0M-6.7%	$9.7M-11.4%	$10.9M-13.9%	$12.7M-0.1%	$12.7M-14.5%	$14.9M+23.3%	$12.1M
Retained Earnings	-$269.3M-2.6%	-$262.4M-1.8%	-$257.7M-0.6%	-$256.3M-1.1%	-$253.6M-1.2%	-$250.5M-1.4%	-$247.1M-0.8%	-$245.0M

EKSO Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

EKSO quarterly cash flow statement

Metric	TTM	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12
Operating Cash Flow	-$12.0M	-$11.8M-19.9%	-$9.8M+18.3%	-$12.1M+17.9%	-$14.7M-31.7%	-$11.2M-27.4%	-$8.8M+44.5%	-$15.8M+28.8%	-$22.2M+29.0%	-$31.2M-24.9%	-$25.0M-36.8%	-$18.3M-21.7%	-$15.0M-65.6%	-$9.1M-76503.8%	-$12K
Capital Expenditures	$178K	$188K+408.1%	$37K-76.4%	$157K-19.1%	$194K+228.8%	$59K	$0-100.0%	$60K-54.2%	$131K-71.3%	$456K-58.4%	$1.1M-26.5%	$1.5M+0.3%	$1.5M+292.3%	$379K	N/A
Free Cash Flow	-$12.1M	-$12.0M-21.3%	-$9.9M+19.1%	-$12.2M+17.9%	-$14.9M-32.7%	-$11.2M-28.1%	-$8.8M+44.7%	-$15.8M+29.0%	-$22.3M+29.6%	-$31.7M-21.4%	-$26.1M-32.0%	-$19.8M-19.8%	-$16.5M-74.7%	-$9.4M	N/A
Investing Cash Flow	-$178K	-$188K-408.1%	-$37K+76.4%	-$157K+97.0%	-$5.2M-8671.2%	-$59K	$0+100.0%	-$60K+54.2%	-$131K+71.3%	-$456K+58.4%	-$1.1M+26.5%	-$1.5M	N/A	N/A	N/A
Financing Cash Flow	$8.1M	$6.6M-14.7%	$7.8M+2132.5%	$348K	$0-100.0%	$38.7M+261.7%	$10.7M-43.8%	$19.0M+737.6%	$2.3M-94.7%	$42.6M+82.6%	$23.3M+65.0%	$14.1M	N/A	N/A	$42K

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Operating Cash Flow	-$2.1M+51.0%	-$4.3M-110.1%	-$2.1M+40.2%	-$3.4M-75.3%	-$2.0M-37.1%	-$1.4M+37.1%	-$2.3M+14.7%	-$2.7M
Capital Expenditures	$0-100.0%	$126K+950.0%	$12K-70.0%	$40K+300.0%	$10K-52.4%	$21K+162.5%	$8K	$0
Free Cash Flow	-$2.1M+52.4%	-$4.5M-115.0%	-$2.1M+40.5%	-$3.5M-76.4%	-$2.0M-35.8%	-$1.5M+36.4%	-$2.3M+14.4%	-$2.7M
Investing Cash Flow	$0+100.0%	-$126K-950.0%	-$12K+70.0%	-$40K-300.0%	-$10K+52.4%	-$21K-162.5%	-$8K	$0
Financing Cash Flow	$5.0M+69.5%	$2.9M+768.4%	-$437K-170.9%	$616K-82.5%	$3.5M+1223.9%	-$314K-106.7%	$4.7M+1870.2%	-$265K

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

EKSO Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples.

EKSO quarterly financial ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12
Gross Margin	53.5%+0.4pp	53.1%+3.4pp	49.7%+1.5pp	48.1%-11.9pp	60.0%+2.9pp	57.1%+8.5pp	48.6%+10.6pp	38.0%+9.9pp	28.1%+7.4pp	20.7%+7.1pp	13.6%-15.7pp	29.3%+11.5pp	17.8%	N/A
Operating Margin	-104.1%	-58.4%+24.3pp	-82.7%	-120.5%	-123.0%	-149.6%	-119.6%	-238.5%	-429.9%	-194.0%	-248.9%	-315.3%	-311.8%	N/A
Net Margin	-91.4%-28.2pp	-63.2%+19.9pp	-83.1%	-116.8%	-86.8%	-178.2%	-87.2%	-238.2%	-396.1%	-165.0%	-226.2%	-633.9%	-360.0%	N/A
Return on Equity	-129.6%-40.4pp	-89.2%+31.4pp	-120.6%-61.3pp	-59.3%-33.0pp	-26.2%+330.7pp	-356.9%-178.4pp	-178.5%+810.9pp	-989.4%-853.3pp	-136.1%+223.2pp	-359.4%-136.9pp	-222.4%-74.3pp	-148.1%	N/A	N/A
Return on Assets	-58.1%-15.6pp	-42.5%+10.0pp	-52.6%-15.7pp	-36.9%-17.0pp	-19.9%+57.0pp	-76.8%-21.5pp	-55.4%+97.5pp	-152.9%-76.2pp	-76.7%+19.4pp	-96.1%-35.2pp	-60.8%+40.0pp	-100.9%+79.7pp	-180.5%	N/A
Current Ratio	1.63-0.9x	2.500.0x	2.49-0.9x	3.37-3.6x	6.97+3.3x	3.70+1.3x	2.40+0.9x	1.48-2.3x	3.81+0.5x	3.27+0.3x	2.92-1.5x	4.43+4.2x	0.27	N/A
Debt-to-Equity	1.23+0.1x	1.10-0.2x	1.29+0.7x	0.61+0.6x	0.05-0.4x	0.45+0.4x	0.06-0.9x	0.97+0.7x	0.23-0.8x	1.04+1.0x	0.030.0x	0.01	N/A	N/A
FCF Margin	-93.7%-38.5pp	-55.1%+11.7pp	-66.8%	-115.3%	-99.7%-1.1pp	-98.6%	-113.8%	-196.8%	-430.9%	-183.5%	-228.2%	-309.6%	-285.9%	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Gross Margin	50.2%-3.1pp	53.2%-7.1pp	60.3%+20.5pp	39.8%-13.7pp	53.5%+0.2pp	53.3%-0.2pp	53.5%+0.2pp	53.3%
Operating Margin	-262.4%	-143.6%	-33.2%	-193.2%	-101.9%	-43.8%+20.1pp	-63.9%-16.7pp	-47.2%
Net Margin	-321.6%	-148.8%	-33.6%	-131.7%	-85.7%-18.6pp	-67.0%-16.9pp	-50.2%-1.4pp	-48.8%
Return on Equity	-329.4%-277.7pp	-51.8%-37.1pp	-14.7%+10.1pp	-24.8%-2.0pp	-22.8%+4.1pp	-26.9%-12.9pp	-13.9%+6.1pp	-20.0%
Return on Assets	-35.0%-11.8pp	-23.2%-16.7pp	-6.6%+5.1pp	-11.7%-1.1pp	-10.6%+2.2pp	-12.8%-5.7pp	-7.1%+1.9pp	-8.9%
Current Ratio	1.55-0.1x	1.630.0x	1.66-0.7x	2.380.0x	2.35-0.2x	2.50-0.3x	2.81+0.4x	2.42
Debt-to-Equity	6.66+5.4x	1.230.0x	1.24+0.1x	1.120.0x	1.15+0.1x	1.10+0.1x	0.96-0.3x	1.24
FCF Margin	-99.2%	-141.9%	-49.0%	-169.4%	-58.5%-30.0pp	-28.6%+26.8pp	-55.3%-1.4pp	-53.9%

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.

Similar Companies

FEMASYS INC FEMY

$26.8M

Lucyd Inc LUCY

$8.2M

Meihua International Medical Technologies Co., Ltd. MHUA

$425.4M

Harvard Biosci HBIO

$36.1M

Bionano Genomics Inc BNGO

$13.8M

Where Ekso Bionics Ranks

Frequently Asked Questions

What is Ekso Bionics's annual revenue?

Ekso Bionics (EKSO) reported $12.8M in total revenue for fiscal year 2025. This represents a -28.6% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Ekso Bionics's revenue growing?

Ekso Bionics (EKSO) revenue declined by 28.6% year-over-year, from $17.9M to $12.8M in fiscal year 2025.

Is Ekso Bionics profitable?

No, Ekso Bionics (EKSO) reported a net income of -$11.7M in fiscal year 2025, with a net profit margin of -91.4%.

What is Ekso Bionics's EBITDA?

Ekso Bionics (EKSO) had EBITDA of -$11.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Ekso Bionics's gross margin?

Ekso Bionics (EKSO) had a gross margin of 53.5% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Ekso Bionics's net profit margin?

Ekso Bionics (EKSO) had a net profit margin of -91.4% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Ekso Bionics's return on equity (ROE)?

Ekso Bionics (EKSO) has a return on equity of -129.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Ekso Bionics's free cash flow?

Ekso Bionics (EKSO) recorded an outflow of $12.0M in free cash flow during fiscal year 2025. This represents a -21.3% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Ekso Bionics's operating cash flow?

Ekso Bionics (EKSO) recorded an outflow of $11.8M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Ekso Bionics's total assets?

Ekso Bionics (EKSO) had $20.1M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Ekso Bionics's capital expenditures?

Ekso Bionics (EKSO) invested $188K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Ekso Bionics spend on research and development?

Ekso Bionics (EKSO) invested $3.0M in research and development during fiscal year 2025.

How many shares does Ekso Bionics have outstanding?

Ekso Bionics (EKSO) had 4M shares outstanding as of fiscal year 2025.

What is Ekso Bionics's current ratio?

Ekso Bionics (EKSO) had a current ratio of 1.63 as of fiscal year 2025, which is generally considered healthy.

What is Ekso Bionics's debt-to-equity ratio?

Ekso Bionics (EKSO) had a debt-to-equity ratio of 1.23 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Ekso Bionics's return on assets (ROA)?

Ekso Bionics (EKSO) had a return on assets of -58.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

How does Ekso Bionics's liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, Ekso Bionics (EKSO) held $1.2M in cash, cash equivalents and investments, and reported an operating cash outflow of $11.8M over that year. Dividing the one by the other, the reported balance equals about 1 month of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is Ekso Bionics's Altman Z-Score?

Ekso Bionics (EKSO) has an Altman Z-Score of -17.22, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Ekso Bionics's Piotroski F-Score?

Ekso Bionics (EKSO) has a Piotroski F-Score of 1 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Ekso Bionics's earnings high quality?

Ekso Bionics (EKSO) reported a net loss of $11.7M while operations used $11.8M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Ekso Bionics cover its interest payments?

Ekso Bionics (EKSO) reported an operating loss of $13.3M against $309K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Ekso Bionics?

Ekso Bionics (EKSO) scores 36 out of 100 on our Financial Health Score, indicating weak standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.